{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:33:00Z","timestamp":1740148380869,"version":"3.37.3"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"DOI":"10.1093\/ecco-jcc\/jjae103","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T08:04:55Z","timestamp":1720253095000},"page":"1359-1360","source":"Crossref","is-referenced-by-count":0,"title":["VIBRATO\u2019s Symphony: Orchestrating Biomarker Harmony for Ritlecitinib in UC Therapy"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"first","affiliation":[{"name":"University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven , Leuven , Belgium"},{"name":"KU Leuven, Department of Chronic Diseases and Metabolism , Leuven , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"2024090305533284000_CIT0001","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/ecco-jcc\/jjab050","article-title":"Results of the Seventh Scientific Workshop of ECCO: precision medicine in IBD: disease outcome and response to therapy","volume":"15","author":"Verstockt","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024090305533284000_CIT0002","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis","volume":"6","author":"Alsoud","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024090305533284000_CIT0003","doi-asserted-by":"crossref","first-page":"jjad213","DOI":"10.1093\/ecco-jcc\/jjad213","article-title":"Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis","author":"Hassan-Zahraee","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2024090305533284000_CIT0004","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024090305533284000_CIT0005","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ecco-jcc\/jjad212.0009","article-title":"Op09 oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn\u2019s disease: data from the PIZZICATO umbrella study","volume":"18","author":"Vermeire","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2024090305533284000_CIT0006","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024090305533284000_CIT0007","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjab051","article-title":"Results of the Seventh Scientific Workshop of ECCO: precision medicine in IBD: what, why, and how","volume":"15","author":"Fiocchi","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024090305533284000_CIT0008","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ibd\/izaa281","article-title":"Understanding the molecular drivers of disease heterogeneity in Crohn\u2019s disease using multi-omic data integration and network analysis","volume":"27","author":"Sudhakar","year":"2020","journal-title":"IBD Journal"},{"key":"2024090305533284000_CIT0009","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2021.12.245","article-title":"How do we predict a patient\u2019s disease course and whether they will respond to specific treatments","volume":"162","author":"Verstockt","year":"2022","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae103\/58459933\/jjae103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/9\/1359\/58903588\/jjae103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/9\/1359\/58903588\/jjae103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T05:54:25Z","timestamp":1725342865000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/9\/1359\/7708409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":9,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,5]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae103","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"type":"print","value":"1873-9946"},{"type":"electronic","value":"1876-4479"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,5]]}}}